GO
Loading...

Enter multiple symbols separated by commas

Stocks Eli Lilly and Co

More

  • Where the profits are: 10 picks Monday, 8 Jun 2015 | 8:00 AM ET

    As most U.S. companies struggle to grow profits this year, some S&P 500 firms could be poised to buck the trend, a new report shows.

  • June 6- A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials presented on Saturday. More patients in the studies who received Lilly's basal insulin peglispro also got their blood sugar down to the...

  • FDA panel to discuss Lilly's lung cancer drug approval Tuesday, 2 Jun 2015 | 11:10 AM ET

    June 2- The U.S. Food and Drug Administration said a panel of experts would discuss a marketing application from Eli Lilly& Co on a new targeted lung cancer treatment. The FDA said the panel would review data that showed improved overall survival rate in lung cancer patients treated with a combination of Lilly's experimental drug, necitumumab, and chemotherapy...

  • Trading pharma: 5 plays on Bristol's rough day Friday, 29 May 2015 | 6:47 PM ET
    Bristol-Myers Squibb R&D headquarters.

    Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...

  • U.S. FDA warns on newer class of type 2 diabetes drugs Friday, 15 May 2015 | 11:06 AM ET

    May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization. They include AstraZeneca's Farxiga, J&J's Invokana and...

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • Takeda to take $2.7 bln charge to settle Actos cases Tuesday, 28 Apr 2015 | 8:31 PM ET

    April 28- Takeda Pharmaceutical Co Ltd and its Takeda Pharmaceuticals U.S.A. Inc unit said on Tuesday they reached a $2.4 billion agreement to settle the majority of claims involving the diabetes drug Actos. Takeda said it will take a $2.7 billion charge against earnings to cover the settlement costs in the 2014 fiscal fourth quarter ended March 31.

  • Dollar hits Pfizer; Merck 'blew away' estimates Tuesday, 28 Apr 2015 | 9:04 AM ET
    Tablets of Pfizer Inc.'s Lipitor and Merck & Co.'s Zocor.

    Pfizer reported a 4 percent drop in quarterly revenue, while Merck posted earnings that topped expectations.

  • Strong dollar continues to plague earnings Thursday, 23 Apr 2015 | 11:27 AM ET
    3M

    The big story for earnings season is continuing to play out: The strong dollar is notably affecting revenues for multinationals.

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • April 23- Eli Lilly and Co soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing but stuck to its full-year earnings forecast while revenue fell but matched expectations. Lilly earned $530 million, or 50 cents per share, in the quarter, compared with $728 million, or 68 cents per share, a year earlier..

  • Early movers: PBR, MMM, CAT & more Thursday, 23 Apr 2015 | 8:12 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. In January, the company forecast full-year adjusted earnings of $3.10- $3.20 per share, and sales of $19.50- $20 billion. Lilly on Thursday cut its full-year...

  • Lilly profit falls 27 percent, hurt by strong dollar Thursday, 23 Apr 2015 | 6:32 AM ET

    April 23- Eli Lilly and Co reported a 27 percent fall in quarterly profit, hurt by a stronger dollar. The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. Excluding items, the company earned 87 cents per share.

  • Earnings deluge could support new highs Thursday, 23 Apr 2015 | 6:05 AM ET
    An employee pre-assembles a Caterpillar engine at the Ellicott Dredges facility in Baltimore.

    Investors will eye more earnings amid the possibility of a breakout in stocks to record levels on Thursday.

  • Earnings deluge could support new index highs Wednesday, 22 Apr 2015 | 6:45 PM ET
    An employee pre-assembles a Caterpillar engine at the Ellicott Dredges facility in Baltimore.

    Investors will eye more earnings amid the possibility of a breakout in stocks to record levels on Thursday.

  • LONDON, April 22- Swiss drugmaker Roche has "renewed confidence" that drugs targeting potentially brain-destroying plaque can fight Alzheimer's disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O'Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer's drugs, both of...